NASDAQ:VKTX

Viking Therapeutics - VKTX Stock Forecast, Price & News

$9.23

+0.38 (+4.29%)

(As of 03/27/2023 11:40 AM ET)

Add

Compare

Today's Range: $8.86
▼
$9.54
50-Day Range: $8.40
▼
$11.83
52-Week Range: $2.02
▼
$11.98

Volume: 866,252 shs
Average Volume: 2.14 million shs
Market Capitalization: $723.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.50

Institutional Ownership

Viking Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 92.1% Upside
$17.50 Price Target
Short Interest: Bearish
7.82% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.88
Upright™ Environmental Score
News Sentiment: 1.69
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.96) to ($1.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

538th out of 995 stocks

Pharmaceutical Preparations Industry

248th out of 482 stocks

3.5

Analyst's Opinion

Consensus Rating
Viking Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.50, Viking Therapeutics has a forecasted upside of 92.1% from its current price of $9.11.
Amount of Analyst Coverage
Viking Therapeutics has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.82% of the float of Viking Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Viking Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Viking Therapeutics has recently increased by 9.48%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Viking Therapeutics does not currently pay a dividend.
Dividend Growth
Viking Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Viking Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Viking Therapeutics is -0.88.

3.7

News and Social Media Coverage

News Sentiment
Viking Therapeutics has a news sentiment score of 1.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Viking Therapeutics this week, compared to 1 article on an average week.
Search Interest
37 people have searched for VKTX on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Viking Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Viking Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.50% of the stock of Viking Therapeutics is held by insiders.
Percentage Held by Institutions
Only 34.71% of the stock of Viking Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Viking Therapeutics are expected to decrease in the coming year, from ($0.96) to ($1.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Viking Therapeutics is -10.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Viking Therapeutics is -10.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Viking Therapeutics has a P/B Ratio of 4.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Viking Therapeutics (NASDAQ:VKTX) Stock

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VKTX Stock News Headlines

March 27, 2023 | finance.yahoo.com

Is Viking Therapeutics a Smart Buy on the Dip?

March 21, 2023 | za.investing.com

Viking Therapeutics sell-off is unwarranted, attractive opportunity to add - Truist

March 27, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!

March 18, 2023 | americanbankingnews.com

Viking Therapeutics (NASDAQ:VKTX) Coverage Initiated at StockNews.com

March 18, 2023 | seekingalpha.com

Viking Therapeutics: Some Caution Warranted

March 18, 2023 | nasdaq.com

Stifel Initiates Coverage of Viking Therapeutics (VKTX) with Buy Recommendation

March 17, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About Viking Therapeutics

March 17, 2023 | americanbankingnews.com

Viking Therapeutics (NASDAQ:VKTX) Receives New Coverage from Analysts at Stifel Nicolaus

March 27, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

March 15, 2023 | finance.yahoo.com

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

February 23, 2023 | finance.yahoo.com

2 Surging Healthcare Stocks That Are Still Worth Buying

February 9, 2023 | finanznachrichten.de

Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

February 7, 2023 | finance.yahoo.com

Viking Therapeutics to Present at SVB Securities Global Biopharma Conference

February 7, 2023 | benzinga.com

Viking Therapeutics's Earnings: A Preview

February 7, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Agenus (AGEN) and Viking Therapeutics (VKTX)

February 1, 2023 | finance.yahoo.com

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023

January 16, 2023 | reuters.com

VKTX.OQ - | Stock Price & Latest News | Reuters

January 12, 2023 | finance.yahoo.com

Individual investors account for 50% of Viking Therapeutics, Inc.'s (NASDAQ:VKTX) ownership, while institutions account for 32%

January 9, 2023 | finance.yahoo.com

Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

January 3, 2023 | msn.com

Analyzing Viking Therapeutics's Short Interest

January 3, 2023 | seekingalpha.com

Viking Therapeutics: Booking Profits Following NASH Sympathy Move

December 23, 2022 | benzinga.com

Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today

December 13, 2022 | seekingalpha.com

VKTX Viking Therapeutics, Inc.

November 16, 2022 | finance.yahoo.com

A Viking Therapeutics, Inc. (NASDAQ:VKTX) insider increased their holdings by 68% last year

October 31, 2022 | markets.businessinsider.com

SVB Securities Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)

October 26, 2022 | seekingalpha.com

Viking Therapeutics, Inc. (VKTX) Q3 2022 Earnings Call Transcript

October 26, 2022 | msn.com

Recap: Viking Therapeutics Q3 Earnings

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VKTX Company Calendar

Last Earnings: 2/08/2023
Today: 3/27/2023
Next Earnings (Estimated): 4/26/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VKTX
CUSIP: N/A
CIK: 1607678
Web: www.vikingtherapeutics.com
Phone: (858) 704-4660
Fax: N/A
Employees: 17
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.50
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +87.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-68,870,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -42.77%
Return on Assets: -38.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.61
Quick Ratio: 7.61

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.89 per share
Price / Book: 4.95

Miscellaneous

Outstanding Shares: 78,420,000
Free Float: 74,106,000
Market Cap: $734.01 million
Optionable: Optionable
Beta: 0.77

Key Executives

Brian Lian
President, Chief Executive Officer & Director

Marianne Mancini
Chief Operating Officer

Gregory S. Zante
Chief Financial Officer

Michael Morneau
Vice President-Finance & Administration

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

VKTX Stock - Frequently Asked Questions

Should I buy or sell Viking Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VKTX shares.
View VKTX analyst ratings or view top-rated stocks.
What is Viking Therapeutics' stock price forecast for 2023?: 4 brokers have issued 12 month target prices for Viking Therapeutics' shares. Their VKTX share price forecasts range from $12.00 to $22.00. On average, they anticipate the company's stock price to reach $17.50 in the next year. This suggests a possible upside of 87.0% from the stock's current price.
View analysts price targets for VKTX or view top-rated stocks among Wall Street analysts.
How have VKTX shares performed in 2023?: Viking Therapeutics' stock was trading at $9.40 at the beginning of the year. Since then, VKTX shares have decreased by 0.4% and is now trading at $9.36.
View the best growth stocks for 2023 here.
When is Viking Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our VKTX earnings forecast.
How were Viking Therapeutics' earnings last quarter?: Viking Therapeutics, Inc. (NASDAQ:VKTX) posted its quarterly earnings results on Wednesday, February, 8th. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.03.
What ETFs hold Viking Therapeutics' stock?: ETFs with the largest weight of Viking Therapeutics (NASDAQ:VKTX) stock in their portfolio include SPDR S&P Biotech ETF (XBI), Invesco DWA SmallCap Momentum ETF (DWAS), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC) and

What other stocks do shareholders of Viking Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).
When did Viking Therapeutics IPO?: (VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.
What is Viking Therapeutics' stock symbol?: Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."
Who are Viking Therapeutics' major shareholders?: Viking Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Boxer Capital LLC (1.96%), Two Sigma Investments LP (1.65%), Point72 Asset Management L.P. (1.44%), Renaissance Technologies LLC (1.24%), Dimensional Fund Advisors LP (1.11%) and Geode Capital Management LLC (0.85%). Insiders that own company stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends.
How do I buy shares of Viking Therapeutics?: Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Viking Therapeutics' stock price today?: One share of VKTX stock can currently be purchased for approximately $9.36.
How much money does Viking Therapeutics make?: Viking Therapeutics (NASDAQ:VKTX) has a market capitalization of $734.01 million. The biotechnology company earns $-68,870,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.
How can I contact Viking Therapeutics?: Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.vikingtherapeutics.com. The biotechnology company can be reached via phone at (858) 704-4660 or via email at sdiaz@vidasp.com.

This page (NASDAQ:VKTX) was last updated on 3/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Viking Therapeutics - VKTX Stock Forecast, Price & News

Viking Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Viking Therapeutics (NASDAQ:VKTX) Stock

VKTX Stock News Headlines

VKTX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

VKTX Stock - Frequently Asked Questions

Overall MarketRank^™